Imigran Ftab (Sumatriptan)

Sumatriptan works by selectively stimulating 5‑HT1B and 5‑HT1D serotonin receptors in the brain. This action causes constriction of dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides, thereby interrupting migraine pain pathways.

The dose of Imigran Ftab is determined by a qualified prescriber based on individual patient needs and clinical response. Common tablet strengths include 25 mg, 50 mg, and 100 mg, but the exact regimen should follow the healthcare professional’s instructions.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To order Imigran Ftab, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imigran Ftab belongs to the triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics such as NSAIDs. Compared with other triptans, sumatriptan has a well‑established efficacy profile, but individual response and side‑effect tolerance may vary, making personalized selection important.

Imigran Ftab tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Imigran Ftab is taken orally as a whole tablet with a glass of water. It can be taken with or without food, but swallowing the tablet whole is recommended to ensure proper absorption and rapid onset of action.

Serious risks include coronary vasospasm, myocardial infarction, severe hypertension, serotonin syndrome (especially when combined with other serotonergic drugs), and rare cerebrovascular events such as stroke. Patients should seek immediate medical attention if they experience chest pain, severe headache, or any signs of an allergic reaction.

Imigran Ftab is contraindicated in patients with a history of ischemic heart disease, uncontrolled hypertension, previous stroke or transient ischemic attack, hemiplegic or basilar migraine, and in those taking MAO inhibitors within the past two weeks. It should also be avoided in individuals with known hypersensitivity to sumatriptan.